Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 1997

View Archived Issues

New thrombin inhibitors from Novartis

Abbott reveals compounds for controlling synaptic transmission

Novartis prepares PKC inhibitors

NeoRx licenses Biostent to Schwarz

Menarini prepares thrombin inhibitors

IVAX submits NDA for Paxene

Uriach discloses new antifungal agents

More endothelin antagonists from SKB

Glaxo Wellcome discloses prodrugs of known 5-HT1-like agonist

SKKC and Chinese researchers develop new cancer vaccines

Pivotal trial of Therafectin enrolled

Cardioprotective and cerebroprotective agents from Pierre Fabre

Corvas begins phase Ia trial of rNAPc2

First test for HIV drug resistance introduced in the U.S.

Stromectol available in U.S. for parasitic infections

New experimental data on Asahi Chemical's ART-123

E-456, a minimum functional fragment of thrombomodulin from Asahi Chemical

Sheffield licenses Siemens multidose inhaler

Hematoprotective effects of PEG-rHuMGDF in mice

Electroporation shown to be effective for local delivery of agents for restenosis

Teva's Copaxone launched in U.S.

New experimental data for TPO reported by Kirin Brewery

IVAX's generic acyclovir tentatively approved

Antithrombotic effect of Yamanouchi's YM-337

NeoTherapeutics seeks FDA clearance for AIT-082 clinical trials

Inhibitors of IgE antibody production characterized by Teijin

MT-5, a novel neuritogenic agent from Riken and Taisho

Roberts licenses cardiovascular drug from Pfizer

Amplicor HIV-1 Monitor launched in Japan

Retinoids act as insulin sensitizers in mice

Atrix submits NDA for Atridox

Encouraging results for Targretin in CTCL

Sangstat and Gensia sign ciclosporin manufacturing agreement

Phase I/II results of MedImmune's MEDI-493 reported